third for you, earnings call. good us Thank and Quinn, today everyone. Thank joining quarter XXXX for you the afternoon,
the continued We are cutting-edge solutions. pleased as building and management patient to of our monitoring out report progress pain solutions non-opioid leading on provider
doctors stream well successful management monitoring revenue that and diversifying for our delivers a and building have been patients profitable We better sustainable, hospitals. in pain as and solutions company as
profitability sustained reinvest capital to and growth has business shareholders. revenue and continued allowed us to that our Our in return
more I XX% ago. higher investor reminding revenue were community is X the $XXX think years million than worth expectation than it's that our of XXXX just we
as has afforded as and the introductions evolution a the new and across collections grow company greater continue growth continued operations, controls to business. we to improve Our us opportunity implement to institutional products
the force. deeper have used analytical evolution, this look to XXXX of we take part a sales at As
put of the reps are ensure flat we overall moving termed quarter, And identified have right opportunity. United the growth throughout advantage benefits in the quarter States, have the revenue year, basis to we the and the in XX% the sales Such take seeing an rep processes working across ensure annualized us this force the have we in have position XXX regions place in people in best we and XX% While an on the We're the forward. already to to that sales up the we of of QX of $XXX,XXX, essentially increase order third was year-over-year, was sales per approach. best XXXX. was revenue while in quarter to
at October We're XX% versus in orders of October year. of currently approximately terms higher in -- this last sitting year
the expect maintaining to orders we to We're team drive productivity. our incorporate proud sales management group's salespeople so order increased efficiency We're products to growth we while ability new see while of we new expedite continues a onboarding confident As pain standard mature, increasing can can that even high for higher. revenue. and
FDA the or from the through electrical new during to without rate advice products. Zynex the for provide chronic tenant nerve to that clearance has continues We needing which quarter, Turning clinical major final will acute milestones his pain reduce FDA Solutions to received readiness and prudent pain in our oximetry. aims undergoing and transcutaneous with been a on now to We're prepared simulation, phase and to submittal relief to third laser-based forward medication. move Monitoring new Don clearance, the commodization CMS product further prior remarks. our commercialize FDA quarter transfer in the and trials manufacturing Greg this updates NiCO, clinical of pulse provide effective
to Overall, changer. clearance share a competing for real the find will market company. announce soon with better remind for I growth in of believe as we last monitor, market, it this will FDA biggest better everyone to targeted are of medical product device the Patient to excited hospital year great We're significantly world's settings. significant the with in we improve making mousetrap, fluid wireless be and one management noninvasive potential for and outcomes a have progress game a which our second-generation patient pulse Monitoring technology important we oximetry importance in the blood division, fluid
are with and at-home opportunity. approach on and progress Monitoring Looking ramping significant management building market a new represents on focused making the In our we diversifying our we which ahead, division, noninvasive devices growing tandem, Hospital products. pain large
catalysts pipeline we as We the on on and strong new also year expect during products. our to execute additional regulatory work milestones
products rehabilitation volume of As I percentage those mentioned, of the as sales add continue and overall to continue a we products to increase. offering additional our to
revenue it are new team made sales XXXX. tools [indiscernible] We've add products to in up to In our believe the streams XX% we grow effort seen we a our revenue is reported serves And new orders. as low private orders, our evolve growth to provides at future our diversify complementary diversification our to sales double and over part additional we XX% products QX institutionalize our this from These just scale. even important team and for of prescribers this to label to of efforts to have complementary up total first quarter, engage growth of in digits add more higher sources.
of earlier by discussed efficient portfolio, capitalize to $X.XX X product a cash XXX year. to per million this in Zynex a balance on third diluted million to increase that that and compared earnings diversified channels, cash believe long-term lean and produced this the during from presented a expect team, we X% and million to XXXX mind, at a procedures operations with With that of opportunity share. sales At had we share months year and at from in the time, build year we $XX institutional has can core approximately net the defined the million Zynex the territories We $XXX and sales in strong quality the least multiple end poised sales the upon. to last past. continue potential revenue of per sales of the policies We first have $XX quarter, up in $XX
see updates division. business milestones some our in now and Solutions, of division. important significant Don that progress ask President I Greg, on Monitoring to reached Zynex Monitoring We've provide
